**Arrival and Registration**

**MONDAY, MARCH 28**

**Welcome and Keynote Address**

Pamela J. Bjorkman, California Institute of Technology, USA

* A Molecular Arms Race: The Immune System versus HIV

**Human Immunization**

William Schief, The Scripps Research and IAVI, USA

* Clinical Tests of Germline Targeting

Rogier W. Sanders, University of Amsterdam, Netherlands

* SOSIP Based Immunogens as Vaccines

Margaret Juliana McElrath, Fred Hutchinson Cancer Research Center, USA

* Env Based Immunogenicity in the Clinic

**Therapeutic Antibodies**

Evon M. Cale, NIAID, National Institutes of Health, USA

* Short Talk: Potent and Durable Neutralizing Activity of Intramuscular AAV8-Vectored VRC07 in HIV-1-Infected Patients

Yunda Huang, Fred Hutchinson Cancer Center, USA

* Short Talk: Predicting HIV Prevention Efficacy of a Broadly Neutralizing Antibody (bnAb) Combination in Follow-up to the Antibody Mediated Prevention (AMP) Trials

**Workshop 1**

Andrea Biju, National Institutes of Health, USA

* Base Glycan Covered SOSIP Trimers Reduce Off-Target Immune Response to HIV Envelope Base

Tom G. Caniels, Amsterdam UMC, Netherlands

* A Trimer-Based Germine Targeting HIV-1 Env Vaccination Regimen Selects for Typical Rare Features and Neutralizing Potential of VRC01-Class Antibodies

Alison W. Burns, The Scripps Research Institute, USA

* Isolation of Broadly Neutralizing V3 Glycan Antibodies from an HIV-infected Infant

Erving Fabian Cardozo-Ojeda, Fred Hutchinson Cancer Research Center, USA

* Assessing the Impact of Conditioning and Graft vs Host in Reducing the HIV Reservoir Under Allogeneic Hematopoietic Stem Cell Transplantation

Kiera L. Clayton, University of Massachusetts Medical School, USA

* HIV-Infected Macrophages Resist Efficient NK Cell-Mediated Killing while Preserving Inflammatory Cytokine Responses

Kim-Marie A. Dam, California Institute of Technology, USA

* HIV-1 CD4-Binding Site Germline Antibody–Env Structures Inform Vaccine Design

Tyler Evangelous, Duke Human Vaccine Institute, USA

* High-Throughput Screening of Antigen- Reactive B Cells in SHIV-infected Rhesus Macaques

William Feist, Stanford University, USA

* Establishing Multilayered Genetic Resistance to HIV Through Engineering Hematopoietic Stem Cells for B Cell Specific Secretion of Therapeutic Antibodies

**Passive Therapies**

Glenda E. Gray, South African Medical Research Council, South Africa

* The AMP Study

Marina F. Caskey, Rockefeller University, USA

* Human Studies with Combination bnAbs

Malcolm A. Martin, National Institutes of Health, USA

* Remote Presentation: Antibody Studies in SHIV Infected Macaques

Jesper Damsgaard Gunst, Aarhus University Hospital, Denmark

* Short Talk: The Impact of 3BC117 and Romidepsin Administration at ART Initiation on HIV-1 Persistence: A Randomized, Controlled, Phase Ib/Ila Clinical Trial (the eCLEAR study)

Sarah E. Lovelace, Vaccine Research Center, NIAID, NIH, USA

* Short Talk: Ex vivo Assay Predicts HIV-1 Suppression by bnAbs Infused in a Phase I Clinical Trial

Shawn Barman, The Scripps Research Institute, USA

* Short Talk: Isolation of HIV bnAbs that Target a Novel Quaternary CD4-Binding Site Epitope

**Poster Session 1**

**TUESDAY, MARCH 29**

**Vaccine Immunology**

Gabriel D. Victora, Rockefeller University, USA

* Clonal and Cellular Dynamics in Germinal Centers

Lillian Cohn, Fred Hutchinson Cancer Research Center, USA

* Talk Title to be Announced

Peter D. Kwong, NIAID, National Institutes of Health, USA

* Vaccination Targeting Specific Sites of HIV-1 Vulnerability

James Counts, Duke University, USA

* Short Talk: Elicitation of CH235-like CD4bs Neutralizing Antibodies in Rhesus Macaques

Brian E. Watts, Duke University, USA

* Short Talk: B Cells Discriminate HIV-1 Envelope Protein Affinities by Sensing Antigen Binding Association Rates

Henry Sutton, La Jolla Institute for Immunology, USA

* Short Talk: Long-Lasting Germinal Center Responses to a Priming Immunization with Continuous Proliferation and Somatic Mutation

**Immunization Strategies**

Margaret E. Ackerman, Dartmouth College, USA

* Talk Title to be Announced

Shane Crotty, La Jolla Institute for Immunology, USA

* Increasing the Breadth and Potency of Candidate HIV Vaccine Immune Responses

Darrell J. Irvine, Massachusetts Institute of Technology, USA

* Adjuvants in HIV-1 Vaccination

Christopher O. Barnes, Stanford University, USA

* Structures of HIV-1 Env Trimers Define Antibody-Mediated Neutralization of HIV-1
Yoann Aldon, Amsterdam UMC, Netherlands
Short Talk: Membrane-Bound HIV-1 Env Germline-Targeting Trimers for Delivery by mRNA or saRNA

Payal P. Pratap, The Scripps Research Institute, USA
Short Talk: Using Electron Microscopy Polyclonal Epitope Mapping to Guide Iterative Structure-Based HIV Vaccine Design

Poster Session 2

WEDNESDAY, MARCH 30

HIV Immunology

Penny L. Moore, University of the Witwatersrand and National Institute for Communicable Diseases, South Africa
Remote Presentation: Viral vs. Antibody Diversification during Infection

Alexandra Trkola, University of Zürich, Switzerland
Remote Presentation: Role of the Virus in Dictating the Immune Response

George M. Shaw, University of Pennsylvania, USA
V2 Apex, V3 glycan, CD4bs and Fusion Peptide bNAbs in SHIV-infected Macaques

Derek W. Cain, Duke University, USA
Short Talk: Ionizable Lipid Nanoparticles are Potent Adjuvants for Protein-Based HIV Vaccines in Non-Human Primates

Claudia Cicala, NIAID, National Institutes of Health, USA
Short Talk: HIV Infection of CD4+ Tissue Resident Memory T Cells is Inhibited by MAdCAM Antagonists

Workshop 2

Hui Li, University of Pennsylvania, USA
V3-Glycan Dependent bNAb Induction in Rhesus Macaques Infected with BG505 or CH848 SHIVs

Isa Munoz-Arias, Montreal Clinical Research Institute IRCCM, Canada
HIV-1 Vpr Targets BC0R for Degradation to Counter Polycomb-Dependent Proviral Silencing

Daniel Reeves, Fred Hutchinson Cancer Research Center, USA
Simultaneous Clonality Modeling of CD4+ T Cell Receptors and HIV Proviruses

Ryan S. Roark, Columbia University, USA
Immunogenetic and Structural Features of Rhesus V2 Apex bNAbs: Reveal Striking Similarities to Human V2 Apex bNAbs: Implications for HIV-1 Vaccine Design

Torben Schiffler, Leipzig University, Germany
Germline-Targeting Epitope-Scaffold Primes B Cells to HIV gp41 in Multiple Animal Models andEngages them in Human Blood

Samantha Marie Townsley, Walter Reed Army Institute of Research, USA
Modulations to HIV-1 Specific B Cells Expressing Activation Markers Associate with Antibody Responses within the First 2 Weeks of infection

James E. Voss, The Scripps Research Institute, USA
An in vitro Affinity Maturation Platform to Evaluate Germline Targeting Immunogens

Hua Wang, NIAID, National Institutes of Health, USA
SHIV Inoculation Improves Potency and Breadth of Serum Neutralization in Non-Human Primates with Prior Vaccine-Induced Fusion Peptides-Directed Responses

Wilton B. Williams, Duke University School of Medicine, USA
Shared Recognition Mechanism for V3-Glycan bnAb Lineage Maturation in Primates

Baoshan Zhang, NIAID, National Institutes of Health, USA
Bispecific CAP256.J3LS Antibody with Expanded HIV-1 Neutralization Breadth

Control of Latency

Robert F. Siliciano, Johns Hopkins University School of Medicine, USA
Remote Presentation: In vivo Dynamics of the HIV Reservoir

Sharon R. Lewin, University of Melbourne, Australia
Discovery of Potent Latency Reversing Agents: Novel Targets and Novel Delivery Modalities

Mathias Lichterfeld, Brigham and Women's Hospital, USA
Immune Selection of HIV Reservoir Cells

Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA
How Elite Controllers Control

Amanda Mary Dudek, Stanford University School of Medicine, USA
Short Talk: A Simultaneous Knock-Out Knock-In Gene Editing Strategy Potently Inhibits R5- and X4-Tropic HIV Replication

Helen Wu, Oregon Health & Science University, USA
Short Talk: Long-Term ART-free SIV Remission Following Allogeneic Hematopoietic Cell Transplantation in Mauritian Cynomolgus Macaques

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

THURSDAY, MARCH 31

Departure